<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03680092</url>
  </required_header>
  <id_info>
    <org_study_id>180383</org_study_id>
    <nct_id>NCT03680092</nct_id>
  </id_info>
  <brief_title>Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation in Patients With Hematologic Malignancy</brief_title>
  <official_title>A Randomized Phase II Trial Comparing a Calcineurin Inhibitor-free Graft-versus-host Disease Prophylaxis Regimen With Post-transplantation Cyclophosphamide and Abatacept to Standard of Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dimitrios Tzachanis, MD PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether the combination of cyclophosphamide and
      abatacept versus the treatment used in standard of care will reduce the incidence of moderate
      and severe chronic graft-versus-host disease (GVHD) following hematopoietic stem cell
      transplantation. GVHD occurs when the cells from your donor (the graft) see your body's cells
      (the host) as different and attack them.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The experimental GVHD prophylaxis arm consists of cyclophosphamide and abatacept.
      Cyclophosphamide induces apoptosis of activated T cells and abatacept (CTLA4Ig) blocks
      activation of T cells by inhibiting the co-stimulatory signal.

      Compared to the standard-of-care control arm, the experimental arm is much more convenient
      and expected to be associated with fewer toxicities.

      In addition there is a great theoretical potential for immunological synergy between
      cyclophosphamide and abatacept for inducing post-transplant immunologic tolerance that
      clinically might translate into less GVHD without increase in relapse Patients will be
      randomized 1:1 to the experimental vs the standard of care arm. Randomization will be done
      prior to the use of any conditional therapy.

      The two arms will be stratified by disease (acute leukemia vs others) and donor type (MRD vs
      MUD/MUD vs Haplo) in an effort to keep them balanced.

      The conditioning regimen for both arms will be mainly Busulfan/Fludarabine (A Total Body
      Irradiation based conditioning regimen will be allowed for diseases such as ALL)

      The GVHD prophylaxis regimen on the experimental arm will consist of high dose
      Cyclophosphamide on Days +3 and +4 followed by abatacept for 6 months.

      The GVHD prophylaxis regimen on the standard of care arm will consist of methotrexate on Days
      +1,+3, +6 and +11 and tacrolimus for patients with a 10/10 matched related or unrelated donor
      and of high dose cyclophosphamide on Days +3 and +4 followed by tacrolimus and mycophenolate
      for patients with a haploidentical donor.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 26, 2019</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>occurrence of moderate and severe chronic GVHD at one year post transplant</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>The occurrence of moderate and severe chronic GVHD at one year post Chronic GVHD will be diagnosed and staged according to the previously published and widely accepted National Institutes of Health consensus criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GVHD- and relapse- free survival by one year post transplant</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>GVHD- and relapse- free survival will be defined as the absence of acute GVHD Grade III or IV or moderate or severe chronic GVHD or relapse or non-relapse mortality by one year post transplant. Acute GVHD will be diagnosed and graded according to Glucksberg criteria</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>GVHD</condition>
  <condition>Hematologic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Cyclophosphamide and abatacept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The GVHD prophylaxis regimen on the experimental arm will consist of high dose Cyclophosphamide on Days +3 and +4 followed by abatacept for 6 months. Abatacept at a dose of 10mg/kg will be administered on days +5, +14 and +28, +56, +84, +112, +140, +168</description>
  </arm_group>
  <arm_group>
    <arm_group_label>methotrexate and tacrolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The GVHD prophylaxis regimen on the standard of care arm will consist of methotrexate on Days +1,+3, +6 and +11 and tacrolimus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Day 3 and day 4 following transplant. Dosing will be based on patients' actual weight up to 120% of ideal body weight, above which it will be based on adjusted ideal body weight (ideal weight plus 50% of the difference between ideal and actual weight).</description>
    <arm_group_label>Cyclophosphamide and abatacept</arm_group_label>
    <other_name>cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abatacept</intervention_name>
    <description>Abatacept at a dose of 10mg/kg will be administered on days +5, +14 and +28, +56, +84, +112, +140, +168</description>
    <arm_group_label>Cyclophosphamide and abatacept</arm_group_label>
    <other_name>ORENCIA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>standard of care Methotrexate 5 mg/m2 on Days 1, 3, 6 and 11</description>
    <arm_group_label>methotrexate and tacrolimus</arm_group_label>
    <other_name>Trexall</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Tacrolimus per institutional guidelines</description>
    <arm_group_label>methotrexate and tacrolimus</arm_group_label>
    <other_name>Prograf</other_name>
    <other_name>Astagraf XL</other_name>
    <other_name>Envarsus XR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  High risk hematologic malignancy justifying the need for an allogeneic hematopoetic
             stem cell transplantation: AML, ALL, CML in accelerated or blast phase, MDS/MPN, NHL,
             Hodgkin lymphoma, and multiple myeloma

          -  Creatinine clearance &gt; 40

          -  Adequate hepatic function

          -  Normal cardiac function (EF &gt; 50%)

        Exclusion Criteria:

          -  Patients with hematologic malignancies for which transplant is not the only curative
             option, such as AML with good or intermediate cytogenetics or molecular markers in CR1
             or CML in chronic phase

          -  Inability to identify an 10/10 HLA-Matched Donor (related or unrelated) or a
             haploidentical donor

          -  Active malignant disease relapse

          -  Active, uncontrolled infection, uncontrolled cardiac angina, symptomatic congestive
             heart failure

          -  Life expectancy &lt;3 months

          -  Pregnancy or lactation

          -  Patients may not be receiving any other investigational agents in the last 28 days

          -  Patients with chronic myeloid leukemia in first chronic phase
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dimitrios Tzachanis, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Divya Koura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dimitrios Tzachanis, MD PhD</last_name>
    <phone>858-534-2185</phone>
    <email>dtzachanis@ucsd.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jessika Reiner</last_name>
    <email>jreiner@ucsd.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 19, 2018</study_first_submitted>
  <study_first_submitted_qc>September 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2018</study_first_posted>
  <last_update_submitted>January 9, 2020</last_update_submitted>
  <last_update_submitted_qc>January 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Dimitrios Tzachanis, MD PhD</investigator_full_name>
    <investigator_title>Assistant Clinical Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>Graft-Versus-Host Disease</keyword>
  <keyword>Hematologic Neoplasms</keyword>
  <keyword>Abatacept</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>GVHD prophylaxis</keyword>
  <keyword>stem cell transplantation</keyword>
  <keyword>High risk hematologic malignancy</keyword>
  <keyword>hematologic malignancy</keyword>
  <keyword>Allogeneic Hematopoetic Stem Cell Transplantation</keyword>
  <keyword>GVHD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Abatacept</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

